secwatch.observer — SEC 8-K summary
======================================

Issuer:     Advanced Biomed Inc. (ADVB)
CIK:        0001941029
Form:       8-K
Filed at:   2026-06-30T20:34:32+00:00
Accession:  0001213900-26-073735
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Advanced Biomed sells Taiwan subsidiary for $490k; retains AI operations
------------------------------------------------------------------------

- Sale of 100% of Taiwan subsidiary for $490k cash to buyer Miaozhu Zhao.
- Taiwan subsidiary conducts biomedical R&D including A+PerfusC integrated perfusion 3D cell culture platform.
- Company will continue AI-focused operations through Acellent Technologies (Hong Kong) Co. Limited.
- Closing expected within three months from June 30, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1941029/000121390026073735/0001213900-26-073735-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1941029/000121390026073735/ea0296529-8k_advanced.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-073735

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer